2024-25年,印度的API出口超过进口,政府鼓励刺激国内生产和就业。 India’s API exports exceeded imports in 2024–25, driven by government incentives boosting domestic production and jobs.

卫生部长J P Nadda表示, 印度的API出口量在2024-25年间达到41,500克朗, 超过进口量39,215克朗。 India's API exports reached ₹41,500 crore in 2024–25, surpassing imports of ₹39,215 crore, according to Health Minister J P Nadda. 政府在2020年和2021年启动的与生产有关的奖励计划促进了国内关键药物成分的制造,导致当地新生产了Penicillin和Clavulanic酸等药物。 The government's production-linked incentive schemes, launched in 2020 and 2021, have boosted domestic manufacturing of key pharmaceutical ingredients, leading to new local production of drugs like Penicillin and Clavulanic Acid. 现在国内生产的API超过190种, 投资超过目标, 出口和销售大幅增长. Over 190 APIs are now made domestically, investments have exceeded targets, and exports and sales have grown significantly. 这些举措创造了超过1.12万个就业机会,减少了对进口的依赖,政府的目标是到2029年实现自力更生。 The initiatives have created over 1.12 lakh jobs and reduced import dependence, with the government aiming for self-reliance by 2029.